{
    "organizations": [],
    "uuid": "4ee2edbd49344db0ed14da1b5aa52601a6260401",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-exelixis-announces-results-from-a/brief-exelixis-announces-results-from-a-phase-2-trial-of-cabozantinib-in-the-first-line-treatment-of-metastatic-radioiodine-refractory-differentiated-thyroid-carcinoma-idUSASB0C5HV",
    "ord_in_thread": 0,
    "title": "Exelixis Announces Results From A Phase 2 Trial Of Cabozantinib In The First-Line Treatment Of Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 13 (Reuters) - Exelixis Inc:\n* EXELIXIS ANNOUNCES RESULTS FROM A PHASE 2 INVESTIGATOR-SPONSORED TRIAL OF CABOZANTINIB IN THE FIRST-LINE TREATMENT OF METASTATIC RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CARCINOMA\n* EXELIXIS INC - ‍EXELIXIS PLANS TO INITIATE A PIVOTAL PHASE 3 TRIAL LATER THIS YEAR​\n* EXELIXIS INC - ‍54 PERCENT OBJECTIVE RESPONSE RATE AND 43 PERCENT STABLE DISEASE OBSERVED AMONG 35 EVALUABLE PATIENTS​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-14T05:24:00.000+02:00",
    "crawled": "2018-02-14T12:36:48.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "exelixis",
        "inc",
        "exelixis",
        "announces",
        "result",
        "phase",
        "trial",
        "cabozantinib",
        "treatment",
        "metastatic",
        "differentiated",
        "thyroid",
        "carcinoma",
        "exelixis",
        "inc",
        "plan",
        "initiate",
        "pivotal",
        "phase",
        "trial",
        "later",
        "exelixis",
        "inc",
        "percent",
        "objective",
        "response",
        "rate",
        "percent",
        "stable",
        "disease",
        "observed",
        "among",
        "evaluable",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}